2021
Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers
KLUGAR, Miloslav, Abanoub RIAD, Mohamed MEKHEMAR, Jonas CONRAD, Mayte BUCHBENDER et. al.Základní údaje
Originální název
Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers
Autoři
KLUGAR, Miloslav (203 Česká republika, domácí), Abanoub RIAD (818 Egypt, domácí), Mohamed MEKHEMAR, Jonas CONRAD, Mayte BUCHBENDER, Hans-Peter HOWALDT a Sameh ATTIA (garant)
Vydání
Biology, Basel, MDPI, 2021, 2079-7737
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
10602 Biology , Evolutionary biology
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 5.168
Kód RIV
RIV/00216224:14110/21:00122064
Organizační jednotka
Lékařská fakulta
UT WoS
000688819200001
Klíčová slova anglicky
adverse effects; BTN162 vaccine; ChAdOx1 COVID-19 vaccine; cross-sectional studies; COVID-19 vaccines; drug-related side effects and adverse reactions; Germany; health personnel; mRNA-1273 vaccine; prevalence
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 7. 9. 2021 09:52, Mgr. Tereza Miškechová
Anotace
V originále
Background: the increasing number of COVID-19 vaccines available to the public may trigger hesitancy or selectivity towards vaccination. This study aimed to evaluate the post-vaccination side effects of the different vaccines approved in Germany; Methods: a cross-sectional survey-based study was carried out using an online questionnaire validated and tested for a priori reliability. The questionnaire inquired about demographic data, medical and COVID-19-related anamneses, and local, systemic, oral, and skin-related side effects following COVID-19 vaccination; Results: out of the 599 participating healthcare workers, 72.3% were females, and 79.1% received mRNA-based vaccines, while 20.9% received a viral vector-based vaccine. 88.1% of the participants reported at least one side effect. Injection site pain (75.6%) was the most common local side effect, and headache/fatigue (53.6%), muscle pain (33.2%), malaise (25%), chills (23%), and joint pain (21.2%) were the most common systemic side effects. The vast majority (84.9%) of side effects resolved within 1–3 days post-vaccination; Conclusions: the mRNA-based vaccines were associated with a higher prevalence of local side effects (78.3% vs. 70.4%; Sig. = 0.064), while the viral vector-based vaccine was associated with a higher prevalence of systemic side effects (87.2% vs. 61%; Sig. < 0.001). Females and the younger age group were associated with an increased risk of side effects either after mRNA-based or viral vector-based vaccines. The gender- and age-based differences warrant further rigorous investigation and standardized methodology.
Návaznosti
LTC20031, projekt VaV |
| ||
MUNI/A/1608/2020, interní kód MU |
| ||
MUNI/IGA/1543/2020, interní kód MU |
|